Form 4: Shattuck Labs Director Receives Stock Option Grant

Director Neil W. Gibson was granted 81,000 stock options in Shattuck Labs, Inc. as part of an equity compensation arrangement.

Summary

• Director Neil W. Gibson received a grant of 81,000 stock options on May 29, 2026.
• The options have an exercise price of $5.95 per share.
• The options are set to expire on May 29, 2036.
• Vesting occurs on the earlier of the one-year anniversary of the grant date or immediately prior to the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• The value of the options is dependent on the future market performance of Shattuck Labs common stock.

Future Outlook

The options vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The one-year vesting schedule is aligned with typical market practices for director equity awards.

Stakeholder Impact

• Shareholders may experience minor dilution if the options are exercised in the future.

Next Steps

• Vesting of options on the earlier of May 29, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Shattuck Labs, STTK, Director Compensation, Stock Options, Insider Transaction, Equity Grant